High Blood Pressure Treatment: Medications, Lifestyle, and Target Numbers

The Pressure Problem Affecting Half of American Adults

Nearly half of all American adults — approximately 119 million people — have hypertension by the 2017 American College of Cardiology/American Heart Association definition of 130/80 mmHg or higher. Hypertension is the leading modifiable risk factor for stroke, the primary driver of heart failure, and a major cause of chronic kidney disease. The Global Burden of Disease Study identified high systolic blood pressure as the single largest contributor to cardiovascular mortality worldwide, responsible for approximately 10.4 million deaths annually. Blood pressure is a modifiable number, and the evidence for treatment is unambiguous — yet only about 1 in 4 Americans with hypertension has it under control.

The challenge is not the lack of effective treatments. It is diagnosis, adherence, and the persistent underestimation of cumulative cardiovascular risk.

Current Diagnostic Thresholds

The 2017 ACC/AHA guidelines redefined hypertension, lowering the diagnostic threshold from 140/90 to 130/80 mmHg. This reclassification increased the proportion of U.S. adults classified as hypertensive from 32% to 46%, though the threshold for initiating drug therapy remained higher for low-risk individuals.

Blood pressure measurement requires proper technique: seated, arm at heart level, 5 minutes of rest, no caffeine or exercise within 30 minutes. White coat hypertension — elevated readings in clinical settings with normal ambulatory or home measurements — affects 15–30% of patients referred for hypertension; ambulatory blood pressure monitoring (ABPM) is the gold standard for confirming the diagnosis.

Lifestyle Modifications: Real Numbers

Lifestyle changes can produce blood pressure reductions comparable to a single antihypertensive agent. The DASH (Dietary Approaches to Stop Hypertension) diet — rich in fruits, vegetables, and low-fat dairy, restricted in saturated fat and sodium — reduced systolic blood pressure by an average of 11.4 mmHg in hypertensive adults in the original NEJM trial. Combining DASH with a low-sodium diet (1,500 mg/day) produced reductions of up to 14.1 mmHg systolic.

Quantified lifestyle effects on systolic blood pressure:

• Sodium restriction to <2,300 mg/day: approximately 5–6 mmHg reduction
• DASH diet: approximately 8–11 mmHg reduction in hypertensive adults
• Weight loss: approximately 1 mmHg per 1 kg body weight lost
• Aerobic exercise (150 min/week): approximately 5–8 mmHg reduction
• Alcohol reduction to ≤1 drink/day: approximately 4 mmHg reduction
• Smoking cessation: does not directly lower resting blood pressure but removes a major additional cardiovascular risk factor

First-Line Drug Classes

Four drug classes share first-line status for uncomplicated hypertension in most guidelines: thiazide diuretics, ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and calcium channel blockers (CCBs). The ALLHAT trial — the largest antihypertensive outcomes trial ever conducted, enrolling 42,418 participants — found that chlorthalidone (a thiazide-type diuretic) was not inferior to amlodipine (a CCB) or lisinopril (an ACEI) for the primary outcome of fatal coronary heart disease or nonfatal MI, reinforcing the primacy of blood pressure lowering over drug class selection for most patients.

Treatment Targets: The SPRINT Trial

The SPRINT (Systolic Blood Pressure Intervention Trial) trial, published in the New England Journal of Medicine in 2015, randomized 9,361 high-risk adults to either a systolic blood pressure target of <120 mmHg (intensive treatment) or <140 mmHg (standard treatment). The intensive group showed a 25% reduction in major adverse cardiovascular events and 27% reduction in all-cause mortality, but also higher rates of hypotension, syncope, and acute kidney injury events.

Current guideline targets vary by patient population:

• General high-risk adults: <130/80 mmHg (ACC/AHA 2017)
• Adults with diabetes: <130/80 mmHg (ACC/AHA); <140/90 mmHg (ADA and ESC/ESH)
• Adults ≥65 years, community-dwelling: <130 mmHg systolic (based on SPRINT data)
• Adults with CKD without proteinuria: <140/90 mmHg
• Adults with CKD with proteinuria: <130/80 mmHg

Resistant Hypertension

Resistant hypertension — blood pressure above goal despite three antihypertensive agents at maximally tolerated doses, including a diuretic — affects approximately 10–15% of treated hypertensives. Before diagnosing true resistance, clinicians must rule out pseudo-resistance (white coat effect, medication non-adherence, poor measurement technique) and secondary causes: primary aldosteronism (affecting perhaps 10% of hypertensives), obstructive sleep apnea, renal artery stenosis, and pheochromocytoma. Spironolactone, a mineralocorticoid receptor antagonist, is highly effective as a fourth-line agent and reduced blood pressure by 8.7 mmHg systolic versus placebo in the PATHWAY-2 trial.

This article is for informational purposes only. Consult a qualified healthcare professional before making medical decisions.